GlassScriptPhysician profile
Phaxi Yang
NPI 1538751540
$7,863.61
in general payments reported to CMS, 2019-2025
22 companies · $985 in 2025
The $985 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $1,484 · 2023: $1,258 · 2024: $3,582 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,601 · Consulting Fee: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.78 |
| Consulting Fee | $1,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $1,791.26 | 2021-2024 | Mild Device Kit |
| Boston Scientific Corporation | $1,637.62 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Nalu Medical, INC. | $806.32 | 2024-2025 | Nalu Neurostimulation System |
| Nevro Corp. | $741.00 | 2021-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $549.79 | 2021-2023 | Relistor |
| Saluda Medical Americas, INC. | $487.33 | 2024-2025 | Evoke |
| Relievant Medsystems, INC. | $315.63 | 2022-2023 | Intracept |
| Abbvie INC. | $243.26 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $238.80 | 2021-2023 | Xtampza |
| Biotronik Nro, INC. | $197.86 | 2025 | Prospera |
| Globus Medical, INC. | $170.27 | 2025 | Senza |
| Spr Therapeutics, INC | $156.81 | 2022-2024 | Sprint Pns System |
| Medtronic, INC. | $135.76 | 2024 | Intellis Adaptivestim |
| Lilly USA, LLC | $96.00 | 2024 | Mounjaro |
| Scilex Pharmaceuticals INC. | $82.98 | 2022-2023 | Ztlido |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $49.80 | 2025 | |
| Merz Pharmaceuticals, LLC | $40.31 | 2023 | Xeomin |
| Pfizer INC. | $34.99 | 2023 | |
| Painteq LLC | $25.95 | 2021 | |
| Stryker Corporation | $25.24 | 2024 | Mild Device Kit |
| Bioventus LLC | $19.58 | 2024 | Bonescalpel & Sonicone (O.R.) |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaxi Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.